KRAS and non-small cell lung carcinoma: In this evolving therapeutic landscape, the population of patients harboring genomic alterations, including but not limited to, EGFR mutations and ALK rearrangements represents a niche with potentially worse prognosis, in which the use of ICIs in this subgroup of patients is not endorsed based on retrospective data of reduced efficacy in patients with oncogene-addicted NSCLC in the metastatic setting, with the exception of KRAS-mutant NSCLC.